Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2018

01-05-2018 | Thoracic Oncology

Survival Impact of Stations of Pathological Lymph Nodes in N2 Non-small Cell Lung Cancer in a French Hospital

Authors: Christelle Clément-Duchêne, MD, PhD, Amandine Luc, MS, Jean-Matthieu Casse, MD, Jean-Michel Vignaud, MD, PhD, Stéphanie Lacomme, MS, Valentine Anne, MD, Joëlle Siat, MD, Olivier Ménard, MD, Yves Martinet, MD, PhD

Published in: Annals of Surgical Oncology | Issue 5/2018

Login to get access

Abstract

Background

The prognosis of lung cancer remains poor; only 20% of patients can undergo surgery. N2 non-small cell lung cancer (NSCLC) is a heterogeneous disease. We conducted a retrospective study to analyze the impact of N2 location on survival.

Methods

This study included 342 NSCLC with N2 involvement between 1988 and 2014. Patient-related data were collected through the CRB biobank and included demographic, therapeutic, and survival data. Survival was analyzed according to Kaplan-Maier method. Cox’s regression analysis and analysis of variance (ANOVA) were used to determine factors significantly associated with survival.

Results

The population average age was 61.6 years; 82.2% were men, a majority were former smokers (87.1%), and 45.3% had adenocarcinoma. The main prognostic factors were male gender (p = 0.01), number of nodes (p < 0.0001), and tumor size (p < 0.0001). N2 disease had a poor survival (16 months) compared with N0 (32 months) and N1 (21.1 months) disease (p < 0.0001). The patients with involvement of station 4 (survival = 17.8 months) seemed to have a prognosis between those with station 7 (survival = 10.5 months) and N1 (survival = 22.6 months), p = 0.0005.

Conclusions

N2 location has a prognostic impact in surgically NSCLC, and station 4 involvement has a better prognostic than station 7.
Literature
1.
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to THE 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol. 2015;10(9):1240–2.CrossRefPubMed
2.
Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–60.CrossRefPubMed
3.
Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edn). Chest. 2007;132(3 Suppl):29S–55S.
4.
5.
Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013;31(8):992–1001.CrossRefPubMed
6.
Goldstraw P. New staging system: how does it affect our practice? J Clin Oncol. 2013;31(8):984–91.CrossRefPubMed
7.
Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–14.CrossRefPubMed
8.
Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111(6):1718–23.CrossRefPubMed
9.
Clement-Duchene C, Vignaud JM, Stoufflet A, et al. Characteristics of never smoker lung cancer including environmental and occupational risk factors. Lung Cancer. 2010;67(2):144–50.CrossRefPubMed
10.
Alexiou C, Onyeaka CV, Beggs D, et al. Do women live longer following lung resection for carcinoma? Eur J Cardiothorac Surg. 2002;21(2):319–25.CrossRefPubMed
11.
Batevik R, Grong K, Segadal L, Stangeland L. The female gender has a positive effect on survival independent of background life expectancy following surgical resection of primary non-small cell lung cancer: a study of absolute and relative survival over 15 years. Lung Cancer. 2005;47(2):173–81.CrossRefPubMed
12.
de Perrot M, Licker M, Bouchardy C, Usel M, Robert J, Spiliopoulos A. Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J Thorac Cardiovasc Surg. 2000;119(1):21–6.CrossRefPubMed
13.
Ferguson MK, Skosey C, Hoffman PC, Golomb HM. Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol. 1990;8(8):1402–7.CrossRefPubMed
14.
Fu JB, Kau TY, Severson RK, Kalemkerian GP. Lung cancer in women: analysis of the National Surveillance, Epidemiology, and End Results Database. Chest. 2005;127(3):768–77.CrossRefPubMed
15.
Hanagiri T, Sugio K, Uramoto H, et al. Gender difference as a prognostic factor in patients undergoing resection of non-small cell lung cancer. Surg Today. 2007;37(7):546–51.CrossRefPubMed
16.
Ouellette D, Desbiens G, Emond C, Beauchamp G. Lung cancer in women compared with men: stage, treatment, and survival. Ann Thorac Surg. 1998;66(4):1140–3; discussion 1143–4.CrossRefPubMed
17.
Visbal AL, Williams BA, Nichols FC, 3rd, et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg. 2004;78(1):209–15; discussion 215.CrossRefPubMed
18.
Wakelee HA, Wang W, Schiller JH, et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol. 2006;1(5):441–6.CrossRefPubMed
19.
Caldarella A, Crocetti E, Comin CE, Janni A, Pegna AL, Paci E. Gender differences in non-small cell lung cancer: a population-based study. Eur J Surg Oncol. 2007;33(6):763–8.CrossRefPubMed
20.
Foegle J, Hedelin G, Lebitasy MP, Purohit A, Velten M, Quoix E. Specific features of non-small cell lung cancer in women: a retrospective study of 1738 cases diagnosed in Bas-Rhin between 1982 and 1997. J Thorac Oncol. 2007;2(6):466–74.CrossRefPubMed
21.
Zhang J, Gold KA, Lin HY, et al. Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. J Thorac Oncol. 2015;10(4):682–90.CrossRefPubMedPubMedCentral
22.
Legras A, Mordant P, Arame A, et al. Long-term survival of patients with pN2 lung cancer according to the pattern of lymphatic spread. Ann Thorac Surg. 2014;97(4):1156–62.CrossRefPubMed
23.
Yoo C, Yoon S, Lee DH, et al. Prognostic significance of the number of metastatic pN2 lymph nodes in stage IIIA-N2 non-small-cell lung cancer after curative resection. Clin Lung Cancer. 2015;16(6):e203–12.CrossRefPubMed
24.
Kang CH, Ra YJ, Kim YT, Jheon SH, Sung SW, Kim JH. The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer. Ann Thorac Surg. 2008;86(4):1092–7.CrossRefPubMed
25.
Sakuraba M, Takahashi N, Oh S, Miyasaka Y, Inagaki T, Suzuki K. Long-term survival after complete mediastinal lymph node resection and lobectomy in patients with bulky N2 non-small cell lung cancer. Ann Thorac Cardiovasc Surg. 2011;17(2):124–9.CrossRefPubMed
26.
Baba T, Uramoto H, Kuwata T, et al. Survival impact of node zone classification in resected pathological N2 non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 2012;14(6):760–4.CrossRefPubMedPubMedCentral
27.
Fernandes AT, Mitra N, Xanthopoulos E, et al. The impact of extent and location of mediastinal lymph node involvement on survival in stage III non-small cell lung cancer patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(1):340–7.CrossRefPubMed
28.
Guo D, Ni Y, Lv X, Zhang Z, Ye P. Distribution and prognosis of mediastinal lymph node metastases of nonsmall cell lung cancer. J Cancer Res Ther. 2016;12(Supplement):120–5.PubMed
Metadata
Title
Survival Impact of Stations of Pathological Lymph Nodes in N2 Non-small Cell Lung Cancer in a French Hospital
Authors
Christelle Clément-Duchêne, MD, PhD
Amandine Luc, MS
Jean-Matthieu Casse, MD
Jean-Michel Vignaud, MD, PhD
Stéphanie Lacomme, MS
Valentine Anne, MD
Joëlle Siat, MD
Olivier Ménard, MD
Yves Martinet, MD, PhD
Publication date
01-05-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 5/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6373-1

Other articles of this Issue 5/2018

Annals of Surgical Oncology 5/2018 Go to the issue

Gastrointestinal Oncology

Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study

Endocrine Tumors

Predicting Survival and Response to Treatment in Gastroesophageal Neuroendocrine Tumors: An Analysis of the National Cancer Database

Bone and Soft Tissue Sarcomas

Recurrence-Free Survival After Resection of Gastric Gastrointestinal Stromal Tumors Classified According to a Strict Definition of Tumor Rupture: A Population-Based Study

Colorectal Cancer

The Negative Impact of Body Mass Index on the Tumor Microenvironment in Colon Cancer: Results of a Prospective Trial

Thoracic Oncology

Concurrent Versus Sequential Chemoradiation Therapy in Completely Resected Pathologic N2 Non-Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Data Base

Gastrointestinal Oncology

Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience